Misopt Eye Drop is a combination of dorzolamide and timolol, designed to provide effective management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This sterile, preserved-free formulation is administered topically to the affected eye, with the patient lying down or sitting upright. The dorzolamide component, a sulfonamide derivative, inhibits the activity of carbonic anhydrase in the eye, thereby reducing aqueous humor production and intraocular pressure. Timolol, a β-adrenergic receptor antagonist, also contributes to pressure reduction by blocking the effects of epinephrine and norepinephrine on aqueous humor secretion. The combined action of these agents results in a significant and sustained reduction in intraocular pressure, making Misopt Eye Drop a valuable adjunctive therapy for patients requiring pressure control. As with all ocular medications, caution should be exercised when using Misopt Eye Drop, and patients should be carefully monitored for potential side effects, including blurred vision, headache, and conjunctival hyperemia.